Skip to main content
. Author manuscript; available in PMC: 2019 Jan 16.
Published in final edited form as: Immunity. 2018 Jan 16;48(1):147–160.e7. doi: 10.1016/j.immuni.2017.12.004

Figure 1. Melanoma-derived Wnt5a Alters DC Energy Metabolism.

Figure 1

A. Lactate in BMDC culture media from 0–48 hours with rWnt5a treatment. n=6. B. Qrt-PCR analysis of Hk and Pfk expression in DCs following rWnt5a treatment. n=3. C. ECAR (milli-pH units/minute, normalized to 0 min) of untreated (UT) vs. rWnt5a pretreated DCs. Arrow indicates LPS injection. n=6. D. OCR (pico-moles/minute) of DCs pre-treated with rWnt5a or rWnt3a. n=6. Oligo, oligomycin. FCCP, uncoupling agent. Rot, rotenone. E. ECAR of DCs pre-treated with rWnt5a or rWnt3a. n=6. 2DG, 2-deoxyglucose. F. OCR of DCs injected with media alone or concentrated conditioned media (CM) from BrafV600EPten−/−-NTC or -Wnt5aKD cell cultures±rWnt5a. n=6. G. OCR of tumor-infiltrating DCs (TIDCs) isolated from BrafV600EPten−/−-NTC and -Wnt5aKD mice. n=3/group. H. Metabolic parameter calculations based on 1G. n=3/group. KD, knockdown. All data is mean +/- SEM. *P<0.05, **P<0.005. See also Figure S1.